Kliničke studije za Debljina u državi Idaho
21 studija za Debljina traži sudionike na lokacijama u državi Idaho.
Gradovi u državi Idaho
Službeni tekst studije (engleski)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Elite Clinical Trials - Blackfoot /ID# 282042, Blackfoot
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07752979A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Solaris Clinical Research, Meridian
U tijeku regrutacijaFaza 3
Od 8 do 18 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT07253285Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Grand Teton Research Group, Idaho Falls
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Grand Teton Research Group, Idaho Falls
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Family First Medical Center, Idaho Falls
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07392190Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Velocity Clinical Research - Boise, Meridian
U tijeku regrutacijaFaza 3
Od 45 do 99 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Medical Research Partners, Ammon
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Boise
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Boise
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- High Desert Heart and Vascular, Meridian
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Elite Clinical Trials, Blackfoot
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Elite Clinical Trials, Rexburg
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 14. ruj 2026. · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Meridian
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 do 79 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Solaris Clinical Research, Meridian
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Solaris Clinical Research, Meridian
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 27. kol 2026. · NCT07575399A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- High Desert Heart and Vascular PLLC, Meridian
- St. Luke's Idaho Cardiology Associates, Meridian
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Meridian
- ACCOMPLISH-1 Research Site, Rexburg
U tijeku regrutacijaFaza 3
Od 18 do 79 godina · Oba spola · Ažurirano 10. kol 2026. · NCT07654361Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
- Boise VA Medical Center, Boise
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 22. srp 2026. · NCT06390345A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Elite Clinical Trials, Blackfoot
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. srp 2026. · NCT07481630Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.